Progesterone Receptor Negative Active Not Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02971761Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast CancerTreatment
NCT03044730Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by SurgeryTreatment